Trade

with

TearLab Corp
(NASDAQ: TEAR)
AdChoices
2.88
-0.03
-1.03%
After Hours :
-
-
-

Open

2.91

Previous Close

2.91

Volume (Avg)

112.12k (276.27k)

Day's Range

2.80-2.93

52Wk Range

2.80-11.64

Market Cap.

97.74M

Dividend Rate ( Yield )

-

Beta

3.17

Shares Outstanding

33.59M

P/E Ratio (EPS)

-

AdChoices
Fundamentals
  • Key statistics
  • Growth
  • Profitability
  • Financial health
  • Price ratios
  • Trading statistics
Industry Diagnostics & Research
Highlights
Analyst Recommendation: Buy
    • Revenue

    • 14.64M

    • Net Income

    • -28.99M

    • Market Cap.

    • 97.74M

    • Enterprise Value

    • -

    • Net Profit Margin %

    • -108.60

    • PEG (Price/Earnings Growth) Ratio

    • -

    • Beta

    • 3.17

    • Forward P/E

    • -5.06

    • Price/Sales

    • 5.40

    • Price/Book Value

    • 2.79

    • Price/Cash flow

    • -6.55

      • EBITDA

      • -27.12M

      • Return on Capital %

      • -65.92

      • Return on Equity %

      • -92.32

      • Return on Assets %

      • -65.92

      • Book Value/Share

      • 1.04

      • Shares Outstanding

      • 33.59M

      • Last Split Factor (Date)

      • -

      • Last Dividend (Ex-Date)

      • -

      • Dividend Declaration Date

      • -

      Analyst Recommendation
      10/21/2014
      Buy
        • 1 Year Price Target

        • 8.33

        • Credit Rating

        • -

        • Analysts

        • 3

        • EPS Estimate

        • -0.60

        • Cashflow Estimate

        • -

        Morningstar Consensus estimate data
        • Growth Rate (%)

        • Company

        • Industry

          • Sales (Revenue)

            Q/Q (last year)

          • 41.80

          • 21.91

          • Net Income

            YTD/YTD (last year)

          • -

          • -5.55

          • Net Income

            Q/Q (last year)

          • -

          • 0.44

          • Sales (Revenue)

            5-Year Annual Average

          • 99.95

          • 47.82

          • Net Income

            5-Year Annual Average

          • -

          • 4.98

          • Dividends

            5-Year Annual Average

          • -

          • 5.31

          • Profit Margins (%)

          • Company

          • Industry

            • Gross Margin

            • 48.11

            • 42.70

            • Pre-Tax Margin

            • -108.60

            • 11.63

            • Net Profit Margin

            • -108.60

            • 9.55

            • Average Gross Margin

              5-Year Annual Average

            • 38.90

            • 43.76

            • Average Pre-Tax Margin

              5-Year Annual Average

            • -443.40

            • 11.34

            • Average Net Profit Margin

              5-Year Annual Average

            • -399.60

            • 52.13B

            • Financial Ratios

            • Company

            • Industry

              • Debt/Equity Ratio

              • -

              • 0.62

              • Current Ratio

              • 5.99

              • 1.23

              • Quick Ratio

              • 5.45

              • 0.76

              • Interest Coverage

              • -

              • 5.98

              • Leverage Ratio

              • 1.15

              • 2.16

              • Book Value/Share

              • 1.04

              • 14.94

              • Price Ratios

              • Company

              • Industry

                • Current P/E Ratio

                • -5.12

                • 33.44

                • P/E Ratio 5-Year High

                • -25.88

                • 325.07

                • P/E Ratio 5-Year Low

                • -1.33

                • 154.73

                • Price/Sales Ratio

                • 5.57

                • 2.32

                • Price/Book Value

                • 2.88

                • 3.05

                • Price/Cash Flow Ratio

                • -6.55

                • 19.05

                • Key Metrics

                • Company

                • Industry

                  • Return on Equity %

                    (5-Year Average)

                  • -92.32

                    (-113.80)

                  • 9.34

                    (9.80)

                  • Return on Assets %

                    (5-Year Average)

                  • -65.92

                    (-74.00)

                  • 4.63

                    (5.44)

                  • Return on Capital %

                    (5-Year Average)

                  • -92.32

                    (-107.30)

                  • 5.73

                    (6.77)

                  • Income/Employee

                  • -

                  • 17.17k

                  • Inventory Turnover

                  • 5.04

                  • 5.07

                  • Asset Turnover

                  • 0.61

                  • 0.48

                  Current Historical
                  Financials
                  • Income Statement
                  • Balance Sheet
                  • Cash Flow
                  Operating Income
                  -17.77M
                  Operating Margin
                  -121.37
                  Total Equity
                  -
                  Retained Earnings
                  -
                  Free Cashflow
                  -
                  Price/Cashflow
                  -6.55
                  Ownership

                  Institutional Ownership

                  64.95%

                  Top 10 Institutions

                  44.52%

                  Mutual Fund Ownership

                  26.63%

                  Float

                  78.37%

                  5% / Insider Ownership

                  12.60%

                  Corporate insiders or major stockholders reporting trading activity in the stock.

                  Top Mutual Fund Owners

                  Top Institutional Owners

                  Mutual Fund Name

                  Institution Name

                  • Mutual Fund Name

                  • Shares Held

                  • % Change

                  • % Outstanding

                  • MFS® New Discovery Fund

                  •  

                    2,508,481

                  • 0.12

                  • 7.47

                  • MFS® VIT New Discovery Series

                  •  

                    1,087,972

                  • 20.15

                  • 3.24

                  • BMO Small Cap Growth Fund

                  •  

                    997,929

                  • -9.14

                  • 2.97

                  • CI Global Health Sciences Corporate Cl

                  •  

                    802,688

                  • 0.00

                  • 2.39

                  • Vanguard Total Stock Mkt Idx

                  •  

                    457,458

                  • 0.00

                  • 1.36

                  • Strategic Advisers® Small-Mid Cap Fund

                  •  

                    322,518

                  • 30.24

                  • 0.96

                  • Vanguard Extended Market Index Fund

                  •  

                    312,204

                  • 0.00

                  • 0.93

                  • MFS® Core Equity Fund

                  •  

                    286,309

                  • 0.00

                  • 0.85

                  • Ivy Micro Cap Growth Fund

                  •  

                    257,300

                  • 49.42

                  • 0.77

                  • Mutual of America Small Cap Value

                  •  

                    240,598

                  • 0.00

                  • 0.72

                  • Institution Name

                  • Shares Held

                  • % Change

                  • % Outstanding

                  • MFS Investment Management K.K.

                  •  

                    4,900,701

                  • +8.84%

                  • 14.59

                  • BMO Asset Management Inc.

                  •  

                    1,992,384

                  • +25.06%

                  • 5.93

                  • Cortina Asset Management LLC

                  •  

                    1,653,813

                  • +76.93%

                  • 4.92

                  • Wall Street Associates Llc

                  •  

                    1,093,000

                  • +15.14%

                  • 3.25

                  • Altrinsic Global Advisors LLC

                  •  

                    1,063,200

                  • +32.45%

                  • 3.17

                  • Bbt Capital Management, Inc.

                  •  

                    1,000,000

                  • +5.96%

                  • 2.98

                  • BMO Asset Management Corp.

                  •  

                    997,929

                  • -9.14%

                  • 2.97

                  • Vanguard Group, Inc.

                  •  

                    780,662

                  • -8.62%

                  • 2.32

                  • GROW Partners LLC

                  •  

                    600,000

                  • 0.00%

                  • 1.79

                  Company Profile

                  Sector

                  Healthcare

                  Industry

                  Diagnostics & Research

                  Type

                  Distressed

                  Style

                  Small Growth

                  TearLab Corp was incorporated as OccuLogix, Inc. in Delaware in 2002. The Company is an in-vitro diagnostic company based in San Diego, California. The Company is commercializing a proprietary tear testing platform, the TearLab Osmol...morearity System that enables eye care practitioners to test for sensitive and specific biomarkers using nanoliters of tear film at the point-of-care. The Company’s first product measures tear film osmolarity for the diagnosis of Dry Eye Disease, or DED. TearLab Research, Inc. its wholly-owned subsidiary, develops technologies to enable eye care practitioners to test biomarkers (chemistries, metabolites (i.e. glucose), genes and proteins) at the point-of-care. The Company’s first product, the TearLab Osmolarity System, enables the rapid measurement of tear osmolarity in the ...moredoctor's office. Osmolarity is a quantitative and specific biomarker that has been shown to assist in the diagnosis and disease management of DED. The innovation of the TearLab Osmolarity System is its ability to precisely and rapidly measure osmolarity in nanoliter volumes of tear samples, using an efficient and novel tear collection system at the point of care. The TearLab Osmolarity System consists of the following three components: the TearLab disposable, which is a single-use microfluidic microchip; the TearLab Pen, which is a hand-held device that interfaces with the TearLab disposable; and the TearLab Reader, which is a small desktop unit that allows for the docking of the TearLab Pen and provides a quantitative reading for the operator. The Company relies on two suppliers based in the United States for the manufacture of the Readers and Pens which are key components of the TearLab Osmolarity System. It also relies on a single supplier, MiniFAB (Aust) Pty Ltd. located in Australia, for the manufacture of the test cards which is also a key component of the TearLab Osmolarity System. The Company has licensed multiple patents including eight issued U.S. patents; relating to the TearLab Osmolarity System, three pending U.S. patent applications; eighteen pending patent application countries/regions other than the United States, including six applications in Europe, four applications in Japan, three applications in Canada, two in Australia, one application in Brazil and two applications in Mexico. It has registered the TearLab trademark in the United States, the European Union, Japan, Korea, Mexico, the Russian Federation and Turkey. Its TearLab trademark applications are pending in Canada and China. Government authorities in the United States and other countries extensively regulate, among other things, the research, development, testing, manufacture, labeling, promotion, advertising, distribution and marketing of its product, which is a medical device.lessless

                  Key People

                  Elias Vamvakas

                  CEO/Chairman of the Board/Director

                  Dr. Barry Barresi

                  CEO, Subsidiary

                  William G. Dumencu,C.A.

                  CFO/Treasurer

                  Mr. Paul Smith

                  Vice President, Divisional

                  Mr. Manoj Venkiteshwar

                  Vice President, Divisional

                  • TearLab Corp

                  • 9980 Huennekens Street

                  • San Diego, CA 92121

                  • USA.Map

                  • Phone: +1 858 455-6006

                  • Fax: +1 858 812-0540

                  • tearlab.com

                  Incorporated

                  2002

                  Employees

                  101

                  Send Feedback

                  We appreciate your input!

                  • I'm having trouble signing into my Microsoft account

                  • I’m having problems with the services stripe (Mail, Facebook, etc.)

                  • There is an issue with my weather information

                  • I see an error in the content

                  • Other

                  Please give an overall site rating: